Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 289

1.

Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).

Miyauchi E, Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, Gemma A, Saijo Y, Yoshizawa H, Hagiwara K, Nukiwa T; North-East Japan Study Group.

Jpn J Clin Oncol. 2015 Apr 15. pii: hyv054. [Epub ahead of print]

PMID:
25877748
2.

An open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.

Komatsu Y, Okita K, Yuki S, Furuhata T, Fukushima H, Masuko H, Kawamoto Y, Isobe H, Miyagishima T, Sasaki K, Nakamura M, Ohsaki Y, Nakajima J, Tateyama M, Eto K, Minami S, Yokoyama R, Iwanaga I, Shibuya H, Kudo M, Oba K, Takahashi Y.

Cancer Sci. 2015 Apr 15. doi: 10.1111/cas.12675. [Epub ahead of print]

PMID:
25872578
3.

Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutation.

Fukuhara T, Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Saijo Y, Hagiwara K, Morita S, Nukiwa T.

Lung Cancer. 2015 May;88(2):181-6. doi: 10.1016/j.lungcan.2015.02.004. Epub 2015 Feb 9.

4.

Aqueous nanosilica dispersants for carbon nanotube.

Matsuda T, Minami D, Khoerunnisa F, Sunaga M, Nakamura M, Utsumi S, Itoh T, Fujimori T, Hayashi T, Hattori Y, Endo M, Isobe H, Onodera H, Kaneko K.

Langmuir. 2015 Mar 17;31(10):3194-202. doi: 10.1021/la504599b. Epub 2015 Mar 3.

PMID:
25706991
5.

Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.

Sugawara S, Oizumi S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Yoshizawa H, Ito K, Gemma A, Nishitsuji M, Harada M, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Kurihara M, Nukiwa T; North East Japan Study Group and Tokyo Cooperative Oncology Group.

Ann Oncol. 2015 Feb 10. pii: mdv063. [Epub ahead of print]

PMID:
25669832
6.

[Feasibility of short volume hydration in patients with lung cancer treated with Cisplatin-containing chemotherapy].

Ohhara Y, Isobe H, Ito K, Fuke S, Kojima T, Saito H, Nishiura Y.

Gan To Kagaku Ryoho. 2015 Jan;42(1):57-61. Japanese.

PMID:
25596680
7.

Randomized controlled trial comparing docetaxel-cisplatin combination with weekly docetaxel alone in elderly patients with advanced non-small-cell lung cancer: Japan Clinical Oncology Group (JCOG) 0207†.

Tsukada H, Yokoyama A, Goto K, Shinkai T, Harada M, Ando M, Shibata T, Ohe Y, Tamura T, Saijo N; Lung Cancer Study Group of the Japan Clinical Oncology Group (JCOG).

Jpn J Clin Oncol. 2015 Jan;45(1):88-95. doi: 10.1093/jjco/hyu176. Epub 2014 Nov 6.

PMID:
25378648
8.

Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.

Kanazawa K, Yokouchi H, Wang X, Ishida T, Fujita Y, Fujiuchi S, Harada T, Harada M, Takamura K, Oizumi S, Kinoshita I, Katsuura Y, Honjo O, Kojima T, Dosaka-Akita H, Isobe H, Munakata M, Nishimura M; Hokkaido Lung Cancer Clinical Study Group.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1149-57. doi: 10.1007/s00280-014-2589-3. Epub 2014 Oct 8.

PMID:
25294632
9.

Cyclo-meta-phenylene revisited: nickel-mediated synthesis, molecular structures, and device applications.

Xue JY, Ikemoto K, Takahashi N, Izumi T, Taka H, Kita H, Sato S, Isobe H.

J Org Chem. 2014 Oct 17;79(20):9735-9. doi: 10.1021/jo501903n. Epub 2014 Oct 8.

PMID:
25265340
10.

Feasibility study of immediate pharyngeal cooling initiation in cardiac arrest patients after arrival at the emergency room.

Takeda Y, Kawashima T, Kiyota K, Oda S, Morimoto N, Kobata H, Isobe H, Honda M, Fujimi S, Onda J, I S, Sakamoto T, Ishikawa M, Nakano H, Sadamitsu D, Kishikawa M, Kinoshita K, Yokoyama T, Harada M, Kitaura M, Ichihara K, Hashimoto H, Tsuji H, Yorifuji T, Nagano O, Katayama H, Ujike Y, Morita K.

Resuscitation. 2014 Dec;85(12):1647-53. doi: 10.1016/j.resuscitation.2014.09.014. Epub 2014 Sep 28.

11.

Cyclooxygenase-2 inhibitors for non-small-cell lung cancer: A phase II trial and literature review.

Yokouchi H, Kanazawa K, Ishida T, Oizumi S, Shinagawa N, Sukoh N, Harada M, Ogura S, Munakata M, Dosaka-Akita H, Isobe H, Nishimura M.

Mol Clin Oncol. 2014 Sep;2(5):744-750. Epub 2014 Jun 19.

12.

Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).

Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C.

Oncology. 2014;87(1):7-20. doi: 10.1159/000360989. Epub 2014 Jun 24.

PMID:
24968756
13.

Photoinduced electron transfer in a dynamic supramolecular system with curved π-structures.

Hitosugi S, Ohkubo K, Iizuka R, Kawashima Y, Nakamura K, Sato S, Kono H, Fukuzumi S, Isobe H.

Org Lett. 2014 Jun 20;16(12):3352-5. doi: 10.1021/ol501381x. Epub 2014 Jun 11.

PMID:
24918189
14.

Solid-state structures of peapod bearings composed of finite single-wall carbon nanotube and fullerene molecules.

Sato S, Yamasaki T, Isobe H.

Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8374-9. doi: 10.1073/pnas.1406518111. Epub 2014 May 27.

15.

Disilanyl double-pillared bisternaphthyl (SiDPBT): synthesis and interfused packing structures with herringbone and π-stack motifs.

Nakanishi W, Matsuyama N, Hara D, Saeki A, Hitosugi S, Seki S, Isobe H.

Chem Asian J. 2014 Jul;9(7):1782-5. doi: 10.1002/asia.201402290. Epub 2014 May 21.

PMID:
24850222
16.
17.

Water oxidation chemistry of a synthetic dinuclear ruthenium complex containing redox-active quinone ligands.

Isobe H, Tanaka K, Shen JR, Yamaguchi K.

Inorg Chem. 2014 Apr 21;53(8):3973-84. doi: 10.1021/ic402340d. Epub 2014 Apr 2.

PMID:
24694023
18.

Generalized approximate spin projection calculations of effective exchange integrals of the CaMn4O5 cluster in the S1 and S3 states of the oxygen evolving complex of photosystem II.

Isobe H, Shoji M, Yamanaka S, Mino H, Umena Y, Kawakami K, Kamiya N, Shen JR, Yamaguchi K.

Phys Chem Chem Phys. 2014 Jun 28;16(24):11911-23. doi: 10.1039/c4cp00282b.

PMID:
24632787
19.

Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.

Watanabe S, Minegishi Y, Yoshizawa H, Maemondo M, Inoue A, Sugawara S, Isobe H, Harada M, Ishii Y, Gemma A, Hagiwara K, Kobayashi K.

J Thorac Oncol. 2014 Feb;9(2):189-94. doi: 10.1097/JTO.0000000000000048.

20.

Asymmetric autocatalysis initiated by finite single-wall carbon nanotube molecules with helical chirality.

Hitosugi S, Matsumoto A, Kaimori Y, Iizuka R, Soai K, Isobe H.

Org Lett. 2014 Feb 7;16(3):645-7. doi: 10.1021/ol403384q. Epub 2014 Jan 13.

PMID:
24417337
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk